Fuchs P C, Barry A L, Brown S D, Sewell D L
Clinical Microbiology Institute, Tualatin, Oregon 97062, USA.
Eur J Clin Microbiol Infect Dis. 1996 Aug;15(8):678-82. doi: 10.1007/BF01691159.
The activity of the new fluoroquinolone trovafloxacin (CP-99,219) was compared with that of ciprofloxacin and ofloxacin against 517 bacterial isolates representing 50 different species. Against members of the family Enterobacteriaceae, all three drugs showed good in vitro activity. Against most anaerobic bacteria, Staphylococcus, Streptococcus, and Enterococcus species, trovafloxacin was four- to sixteenfold more active than ciprofloxacin. For disk diffusion testing, 10 micrograms trovafloxacin disks gave satisfactory results. Tentative criteria are proposed for use during clinical studies.
将新型氟喹诺酮曲伐沙星(CP-99,219)的活性与环丙沙星和氧氟沙星针对代表50个不同菌种的517株细菌分离株的活性进行了比较。针对肠杆菌科成员,这三种药物均显示出良好的体外活性。针对大多数厌氧菌、葡萄球菌、链球菌和肠球菌属菌种,曲伐沙星的活性比环丙沙星高4至16倍。对于纸片扩散试验,10微克曲伐沙星纸片给出了满意的结果。提出了在临床研究期间使用的暂行标准。